Allogeneic hematopoietic SCT (Allo-HSCT) using reduced-intensity conditioning (RIC) and non-myeloablative conditioning (NMAC) can be curative for patients with high risk or recurrent hematologic cancers including non-Hodgkin lymphoma (NHL). [1] [2] [3] Matched related donors (MRDs) are currently the preferred choice for Allo-HSCT, however, as most patients lack a MRD, the search for an alternative hematopoietic cell source increasingly includes unrelated donors (UDs), unrelated cord blood and eventually haploidentical related donors (HRDs). A newly developed approach for HRD Allo-HSCT using T-cell-replete BM grafts in combination with post-transplantation CY treatment to prevent GVHD and graft rejection has demonstrated promising results, including low rates of non-relapse mortality (NRM) and severe GVHD. [4] [5] [6] [7] The aim of this report is to compare HRD with UD and MRD in a retrospective cohort of chemosensitive NHL patients.
Calmettes (Marseille, France) and Humanitas Cancer Center (Rozzano, Italy). A total of 26, 28, and 25 patients were transplanted with a HRD, UD and MRD.
The median follow-up was 27 months (range 9-67). Patient characteristics are summarized in Table 1 . In the UD group, three patients had an HLA mismatch on one allele. Half of the patients in the HRD group received non-manipulated BM as the stem cell source and the remaining half received PBSC as did all the UD patients. Patient's characteristics were well balanced between the three groups but patients transplanted with UD were older (61 years old) than the remaining patients (53 (HRD) and 55 (MRD) years old, (P = 0.007 and P = NS, respectively)) and median followup was shorter in the HRD group (22 months) than in the MRD group (34 months, P = 0.005) and the UD group (33 months, P = 0.05).
For the entire cohort, grade 2-4 and grade 3-4 acute GVHD incidences were 34% and 15%, respectively, without any significant difference among the three groups of patients. In the entire cohort, 1-year incidence of overall chronic GVHD and severe chronic GVHD was 24% and 10%, respectively. Overall, chronic GVHD rate in the HRD group was 15% as compared with UD (29% (P = NS)) and MRD (29% (P = NS)). Furthermore, in the HRD group, no patient developed severe chronic GVHD compared with 21% in the UD group (P = 0.01) ( Figure 1a ) and 4% in the MRD group (P = NS).
Two-year OS and PFS were 77% and 71%, respectively, for the entire cohort without any significant difference among the three groups (77% and 65% (HRD), 71% and 68% (UD), and 83% and 80% (MRD) for OS and PFS, respectively). Survival rate without relapse or severe chronic GVHD was 10% higher in the HRD group (65%; Figure 1b ) and in the MRD group (66%) in comparison with the UD group (54%, P = NS). Relapse incidence was 15%, for the entire cohort without any significant differences (19% vs 7% vs 20% for HRD, UD and MRD, respectively, P = NS). In the HRD group, 15% of patients died of NRM compared with 27% in the UD group (P = NS), whereas no patients in the MRD group died of toxic complication (P = 0.04 and 0.007, respectively). NRM in the UD cohort was related to acute or chronic GVHD in every case, whereas no death was related to GVHD in the HRD cohort.
Bacterial infection rate was 65% in the HRD group and 60% in the UD group (P = NS), whereas patients in the MRD group had a 20% rate (P = 0.001 and P = 0.004 respectively). There was no statistical difference for CMV reactivation between the three groups (42%, 28% and 28% in the HRD, UD and MRD cohorts, respectively). We observed three cases of probable pulmonary invasive aspergillosis (two cases in the HRD group and one case in the UD group); 2 BK virus hemorrhagic cystitis (one case in the UD and one in the MRD group). We also noticed one lethal documented case of progressive multifocal leukoencephalopathy, in the HRD group. This report of advanced NHL patients who underwent a first Allo-HSCT with HRD, UD or MRD donor conditioned by homogeneous RIC/NMAC shows encouraging results in this aged and heavily pretreated population of patients confirming efficacy of RIC Allo-HSCT in NHL recently reported. 1 The incidences of both acute and chronic GVHD are lower in the three groups of patients than in previously reported series of NHL Allo-HSCT. 2, 3 In our experience, the two strategies used for GVHD prevention in HRD and in UD/MRD groups are effective. In the HRD cohort, post-infusion CY has been shown to reduce alloreactive T-cells involved in GVHD and graft rejection. [5] [6] [7] 10, 11 In the UD and MRD cohorts, we note that intermediate dose of ATG represents an effective GVHD prophylaxis, although preserving disease control. Strikingly, in our series of patients severe chronic GVHD is lower in the HRD group than in the UD group. Our results concerning GVHD confirm data reported in literature about unmanipulated HRD Allo-HSCT with NMAC and postinfusion CY in NHL. 5, 6, 12 The impact of GVHD on quality of life of survivors is a matter of concerns in many recent studies. 13, 14 Thereby, we have previously elaborated a composite end point that evaluates survival without relapse or severe GVHD. 9 We note that, even if it was no statistically different, this estimate was 10% higher in the HRD group in comparison with the UD group of patients.
Moreover, with a minimum follow-up of 9 months in the three groups of patients and median follow-up of 27 months for the whole cohort (22 months in the HRD cohort), T-replete HRD Allo-HSCT and post-infusion CY does not seem to be associated with a higher rate of relapse in comparison with HLA-identical transplantation. Finally, we note an higher survival in our HRD group than in previous reports of NHL patients 6, 15 (PFS: 71% here compared with 40-50% in the report by Luznik et al. and 40% for T-cell NHL) confirming the efficiency of HRD Allo-HSCT in NHL.
Overall, these data suggest that in chemosensitive NHL, the choice of an HRD conditioned with NMAC and post-infusion CY is challenging the strategy based on the search on an UD in case of lack of MRD. Indeed, feasibility of the procedure appears to be satisfactory and lower severe chronic GVHD-related events are observed than in UD transplantation. This is particularly important in aged patients with a high risk of mortality related to chronic GVHD. Furthermore, the prompt availability of a family donor is likely to decrease the risk that patients progress waiting for an UD given that duration of response can be short, in particular for refractory patients. Finally, more patients without MRD could find a donor. Nevertheless, further analyses with longer follow-up and prospective studies are required to better locate HRD Allo-HSCT according to histology, age or comorbidities.
